Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.
Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.
The Global Initiative for Asthma 2019 guidelines recommend avoiding reliance on reliever inhalers because they increase the risk of exacerbation. The guidance signaled a shift in the use of relievers for managing asthma.
“Controlling asthma and reducing exacerbations requires a balance between controller and reliever medications; however, there is a gap between real-world practice and evidence-based guidelines,” the authors explained. “In addition, adherence rates to controllers are suboptimal, ranging from 15 to 54%.”
The retrospective cohort study was conducted among enrollees of the largest health maintenance organization in Israel with the aim of examining the association between elevated and consistent use of reliever inhalers and corresponding HCU. The study included 977 patients with asthma who were followed up for 6 years.
More than one-fourth (27%) of the patients refilled 3 or more prescriptions of canisters of reliever inhalers during the follow-up. Patients who were consistently refilling 3 or more reliever inhaler canisters annually did not have a higher adherence to maintenance and reliever therapy (MART), but they did have higher adherence to other controllers (0.38 vs 0.24, P < .001).
Patients who consistently refilled 3 or more reliever inhaler canisters annually did not have higher HCU costs than other patients ($5550 vs $5562, P = .107). The researchers found no significant different in the number of emergency department visits between the 2 groups and most other HCU components were comparable as well. Given the higher consumption of medications for the respiratory system, medication costs were higher among the group of patients that consistently refilled 3 or more reliever inhaler canisters annually ($1734 vs $1504, P < .001).
The findings were counter to the authors’ expectations that regular and frequent use of reliever inhalers would be an independent determinant of increased HCU. However, inappropriate use of reliever inhalers was associated with higher adherence to controllers, which was itself associated with increased HCU.
“These results imply that regular and frequent use of reliever inhalers, observed in our study among more than one fourth of the study population, may be a proxy of a more comprehensive phenomenon of inappropriate use of pharmaceutical therapy for asthma management that may indicate uncontrolled asthma, which is associated with elevated HCU costs,” they wrote.
Reference
Hadad R, Likhtenshtein D, Maimon N, Simon-Tuval T. Overuse of reliever inhalers and associated healthcare utilization of asthma patients. Sci Rep. 2020;10(1):19155. doi:10.1038/s41598-020-76280-2.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More